Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ZLY025
- Development stage
- Unknown
- Lead developer
- Guangdong Pharmaceutical University
01
Overview
ZLY025: sourced facts only. name: "Using a metabolically oriented scaffold hopping strategy based on HQ461 and NCT02, we developed ZLY025─a highly potent CCNK degrader (DC50 = 42.7 nM, Dmax >93%)." [PMID:41165741]; target: "Using a metabolically oriented scaffold hopping strategy based on HQ461 and NCT02, we developed ZLY025─a highly potent CCNK degrader (DC50 = 42.7 nM, Dmax >93%)." [PMID:41165741]; developer: "School of Pharmacy, Guangdong Pharmaceutical University, Guangzhou 510006, PR China." [PMID:41165741]; stage: "In the xenografted model, ZLY025 exerted robust antitumor activity by effectively degrading CCNK." [PMID:41165741]
02
Targets
CCNK (Cyclin K)
Beyond the preview
Go deeper on ZLY025.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ZLY025.